Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It also secures US $ 10 million for US launch and commercialization
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
The new solution, built on patented blockchain technology, dynamically adapts to patients' behaviour patterns to make clinical encounters more effective
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Subscribe To Our Newsletter & Stay Updated
